Synthesis and biological evaluation of novel fumagillin and ovalicin analogues

Organic and Biomolecular Chemistry

Volumn 3, Issue 11, 2005, Pages 2150-2154

  Mazitschek, Ralph ^a   Huwe, Axel ^b   Giannis, Athanassios ^b  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; ENZYME INHIBITION; ONCOLOGY; REACTION KINETICS; REDUCTION; SYNTHESIS (CHEMICAL); TOXIC MATERIALS; TUMORS;

BIOLOGICAL EVALUATION; FUMAGILLIN; NATURAL PRODUCTS; OVALICIN;

DRUG PRODUCTS;

ANGIOGENESIS INHIBITOR; CYCLOHEXANE DERIVATIVE; FUMAGILLIN; OVALICIN; SESQUITERPENE; UNSATURATED FATTY ACID;

ARTICLE; SYNTHESIS;

ANGIOGENESIS INHIBITORS; CYCLOHEXANES; FATTY ACIDS, UNSATURATED; SESQUITERPENES;

EID: 20844459615     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/b503163j     Document Type: Article

References (53)

1. WHO, National cancer control programmes: policies and managerial guidelines, 2nd ed., World Health Organization, Geneva, 2002.
2. J. Folkman and N. Engl, J. Med., 1971, 285, 1182-1186.
3. J. Folkman, Nat. Med., 1995, 1, 27-31.
4. P. Carmeliet, Nat. Med., 2000, 6, 389-395.
5. D. W. Foster, in Harrison's Principles of Internal Medicine, 14th ed., ed. A. S. Fauci, E. Braunwald, K. J. Isselbacher, J. D. Wilson, J. B. Martin, D. L. Kasper, S. L. Hauser and D. L. Longo, McGraw Hill, New York, 1998, p. 2075.
6. T. E. Eble and F. R. Hanson, Antibiot. Chemother., 1951, l, 54-58.
7. D. Ingber, T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, H. Brem and J. Folkman, Nature, 1990, 348, 555-557.
8. S. Liu, J. Widom, C. W. Kemp, C. M. Crews and J. Clardy, Science, 1998, 282, 1324-1327.
9. E. C. Griffith, Z. Su, B. E. Turk, S. Chen, Y. H. Chang, Z. Wu, K. Biemann and J. O. Liu, Chem. Biol., 1997, 4, 461-471.
10. B. E. Turk, Z. Su and J. O. Liu, Bioorg. Med. Chem., 1998, 6, 1163-1169.
11. B. E. Turk, E. C. Griffith, S. Wolf, K. Biemann, Y. H. Chang and J. O. Liu, Chem. Biol., 1999, 6, 823-833.
12. H. U. Wang, Z. F. Chen and D. J. Anderson, Cell, 1998, 93, 741-753.
13. 6-nBuLi.
14. C. K. Han, S. K. Ahn, N. S. Choi, R. K. Hong, S. K. Moon, H. S. Chun, S. J. Lee, J. W. Kim, C. I. Hong, D. Kim, J. H. Yoon and K. T. No, Bioorg. Med. Chem. Lett., 2000, 10, 39-43.
15. S. Kim, K. LaMontagne, M. Sabio, S. Sharma, R. W. Versace, N. Yusuff and P. E. Phillips, Cancer Res., 2004, 64, 2984-2987.
16. N. Wernert, A. Stanjek, S. Kiriakidis, A. Hugel, H. C. Jha, R. Mazitschek and A. Giannis, Angew. Chem., Int. Ed., 1999, 38, 3228-3231.
17. B. J. Dezube, J. H. Von Roenn, J. Holden-Wiltse, T. W. Cheung, S. C. Remick, T. P. Cooley, J. Moore, J. P. Sommadossi, S. L. Shriver, C. W. Suckow and P. S. Gill, J. Clin. Oncol., 1998, 16, 1444-1449.
18. C. J. Logothetis, K. K. Wu, L. D. Finn, D. Daliani, W. Figg, H. Ghaddar and J. U. Gutterman, Clin. Cancer Res., 2001, 7, 1198-1203.
19. W. M. Stadler, T. Kuzel, C. Shapiro, J. Sosman, J. Clark and N. J. Vogelzang, J. Clin. Oncol., 1999, 17, 2541-2545.
20. A. P. Kudelka, C. F. Verschraegen and E. Loyer, J. Med., 1998, 338, 991-992.
21. V. Castronovo and D. Belotti, Eur. J. Cancer, 1996, 32A, 2520-2527.
22. W. D. Figg, J. M. Pluda, R. M. Lush, M. W Saville, K. Wyvill, E. Reed and R. Yarchoan, Pharmacotherapy, 1997, 17, 91-97.
23. P. Bhargava, J. L. Marshall, N. Rizvi, W. Dahut, J. Yoe, M. Figuera, K. Phipps, V. S. Ong, A. Kato and M. J. Hawkins, Clin. Cancer Res., 1999, 5, 1989-1995.
24. L. Placidi, E. Cretton-Scott, G. de Sousa, R. Rahmani, M. Placidi and J. P. Sommadossi, Cancer Res., 1995, 55, 3036-3042.
25. G. Zhou, C. W. Tsai and J. O. Liu, J. Med. Chem., 2003, 46, 3452-3454.
26. S. Marui, F. Itoh, Y. Kozai, K. Sudo and S. Kishimoto, Chem. Pharm. Bull., 1992, 40, 96-101.
27. S. Marui and S. Kishimoto, Chem. Pharm. Bull, 1992, 40, 575-579.
28. S. Marui, T. Yamamoto, K. Sudo, H. Akimoto and S. Kishimoto, Chem. Pharm. Bull, 1995, 43, 588-593.
29. V. Rodeschini, J.-G. Boiteau, P. Van de Weghe, C. Tarnus and J. Eustache, J. Org. Chem., 2004, 69, 357-373.
30. E. J. Corey and B. B. Snider, J. Am. Chem. Soc., 1972, 94, 2549-2550.
31. D. Kim, S. K. Ahn, H. Bae, W. J. Choi and H. S. Kim, Tetrahedron Lett., 1997, 38, 4437-4440.
32. D. F. Taber, T. E. Christos, A. L. Rheingold and I. A. Guzei, J. Am. Chem. Soc., 1999, 121, 5589-5590.
33. D. A. Vosburg, S. Weiler and E. J. Sorensen, Angew. Chem., Int. Ed., 1999, 38, 971-974.
34. W. Picoul, R. Urchegui, A. Haudrechy and Y. Langlois, Tetrahedron Lett., 1999, 40, 4797-4800.
35. J.-G. Boiteau, P. Van de Weghe and J. Eustache, Org. Lett., 2001, 3, 2737-2740.
36. D. A. Vosburg, S. Weiler and E. J. Sorensen, Chirality, 2003, 15, 156-166.
37. W. Picoul, O. Bedel, A. Haudrechy and Y. Langlois, Pure Appl. Chem., 2003, 75, 235-249.
38. M. Hutchings, D. Moffat and N. S. Simpkins, SYNLETT, 2001, 661-663.
39. A. Barco, S. Benetti, C. De Risi, P. Marchetti, G. P. Pollini and V. Zanirato, Tetrahedron: Asymmetry, 1998, 9, 2857-2864.
40. E. J. Corey, A. Guzman-Perez and M. C. Noe, J. Am. Chem. Sac., 1994, 116, 12109-12110.
41. S. Bath, D. C. Billington, S. D. Gero, B. Quiclet-Sire and M. Samadi, J. Chem. Soc., Chem. Commun., 1994, 1495-1496.
42. E. J. Corey and J. P. Dittami, J. Am. Chem. Soc., 1985, 107, 256-257.
43. 6-nBuLi.
44. M. Fardis, H. J. Pyun, J. Tario, H. Jin, C. U. Kim, J. Ruckman, Y. Lin, L. Green and B. Hicke, Bioorg. Med. Chem., 2003, 11, 5051-5058.
45. P. W. Rabideau, D. M. Wetzel and D. M. Young, J. Org. Chem., 1984, 49, 1544-1549.
46. Whereas employing methyl lithium in lieu of Grignard reagents yields a mixture of both diastereomers. We assume that the complexation of the aldehyde, apart from steric factors and its spatial fixation is crucial for the excellent stereoselectivity. The configuration of the newly generated stereocenter was assigned by transformation of compound 10 into a dioxydecaline derivative and comparison of the chemical shifts to literature data; see: K. Pihlaja, J. Mattinen and J. Czombos, J. Prakt. Chem./ Chem.-Ztg.. 1997, 339, 77-78.
47. T. B. Grindley, Adv. Carbohydr. Chem., 1998, 53, 17-142.
48. T. W. Greene, P. G. M. Wuts, Protective Groups in Org. Synth., 2nd edn., 1991, p. 317.
49. I. E. Marko, A. Ates, A. Gautier, B. Leroy, J.-M. Plancher, Y. Quesnel and J.-C. Vanherck, Angew. Chem., Int. Ed., 1999, 38, 3207-3209.
50. E. J. Corey and M. Chaykovsky, J. Am. Chem. Soc., 1965, 87, 1353-1364.
51. Depending on reaction time, conditions and number of equivalents of ylide, the major side products were either the a,β-unsaturated ketone or the cyclopropylated consecutive product.
52. The relative configuration of both epoxides was assigned by NOE.
53. K. B. Sharpless and R. C. Michaelson, J. Am. Chem. Soc., 1973, 95, 6136-6137.